Published in final edited form as:

Tetrahedron Lett. 2015 July 8; 56(28): 4215–4219. doi:10.1016/j.tetlet.2015.05.058.

Stellettapeptins A and B, HIV-inhibitory cyclic depsipeptides from the marine sponge *Stelletta* sp

Hee Jae Shin^{a,†}, Mohammad A. Rashid^{a,‡}, Laura K. Cartner^{a,b}, Heidi R. Bokesch^{a,b}, Jennifer A. Wilson^a, James B. McMahon^a, and Kirk R. Gustafson^{a,*}

^aMolecular Targets Laboratory, Center for Cancer Research, National Cancer Institute, Frederick National Laboratory for Cancer Research, Building 562, Room 201, Frederick, MD 21702-1201, USA

^bBasic Science Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD 21702-1201, USA

Abstract

Two new HIV-inhibitory depsipeptides, stellettapeptins A (**1**) and B (**2**), were isolated from an extract of the marine sponge *Stelletta* sp., collected from northwestern Australia. Structures of these cyclic nonribosomal peptides were elucidated on the basis of extensive NMR data analysis, and chemical degradation and derivatization studies. Stellettapeptins contain numerous nonproteinogenic amino acid residues and they are the first peptides reported to contain a 3-hydroxy-6,8-dimethylnon-4-(Z)-enoic acid moiety. Compounds **1** and **2** potently inhibit infection of human T-lymphoblastoid cells by HIV-1_{RF} with EC₅₀ values of 23 and 27 nM, respectively.

Keywords

Depsipeptide; Sponge peptide; *Stelletta*; Anti-HIV

Marine sponges in the genus *Stelletta* have proven to be an extremely rich source of structurally diverse and biologically active natural products.^{1–3} Marine sponges frequently contain nonribosomal peptides that have unusual amino acid residues and aliphatic moieties reminiscent of the mixed nonribosomal peptide synthetase (NRPS)–polyketide synthase (PKS) pathways of microorganisms, which suggests the involvement of symbiotic microbes in their production.⁴ In the course of our search for bioactive metabolites from marine organisms, we obtained two new cyclic depsipeptides from a sponge of the genus *Stelletta*. We report herein the isolation, structure determination, and HIV-inhibitory properties of stellettapeptins A (**1**) and B (**2**).

*Corresponding author. Tel.: +1 301 846 5197; fax: +1 301 846 6851. gustafki@mail.nih.gov..

[†]Permanent address: Marine Natural Products Laboratory, Korea Institute of Ocean Science & Technology, 1270 Sadong, Ansan 426-744, Republic of Korea.

[‡]Permanent address: Department of Pharmaceutical Chemistry, University of Dhaka, Dhaka 1000, Bangladesh. shinhj@kiost.ac (H.J. Shin), rashidma@univdhaka.edu (M.A. Rashid)

Supplementary data

Supplementary data (1D and 2D NMR spectral data, ozonolysis, amino acid analysis, anti-HIV data, and isolation of **1** and **2**) associated with this article can be found, in the online version, at <http://dx.doi.org/10.1016/j.tetlet.2015.05.058>. These data include MOL files and InChIKeys of the most important compounds described in this article.

*Stelletta*peptin A (**1**) was isolated as an amorphous solid, which had a molecular formula of $C_{67}H_{108}N_{16}O_{23}$ from analysis of HRESIMS data coupled with 1H and ^{13}C NMR spectral data (Table 1). The presence of a large number of exchangeable amide NH protons (δ_H 6.80–9.98 ppm) and carbonyl resonances (δ_C 170.0–182.4 ppm) in the 1H and ^{13}C NMR spectra of **1** was characteristic of a peptide derivative. Detailed analysis of 2D NMR data enabled us to assign 11 amino acid residues: *N*-methylalanine (*N*MeAla), β -methoxytyrosine (β -OMeTyr), *N*-methylglutamine (*N*MeGln), leucine (Leu), glycine (Gly), 3-methoxyalanine (3-OMeAla), threonine (Thr), 3,4-dimethylglutamine (3,4-DiMeGln), 2,3-diaminobutanoic acid (Dab), 3-hydroxyglutamine (3-OHGln), and 3-hydroxyasparagine (3-OHAsn) (Table 1). Additionally, a 3-hydroxy-6,8-dimethylnon-4-enoic acid (Hdna) moiety was identified (Fig. 1).

The sequence of amino acid residues in *stellettapeptin* A (**1**) was deduced from inter-residue NH/ $CH\alpha$ ROE interactions, acquired in CD_3OH , and HMBC correlations as shown in Figure 2. The Hdna unit was defined by 1H - 1H COSY and heteronuclear correlation NMR data, and its double bond assigned *Z* geometry based on the 10.5 Hz vicinal coupling between the H-4 (δ_H 5.37) and H-5 (δ_H 5.21) olefin protons. The Hdna moiety was linked to the N-terminus of the 3-OHAsn residue by an HMBC correlation from the 3-OHAsn NH (δ_H 8.25) to the carbonyl (δ_C 175.2) of Hdna. This linkage was also supported by ROESY correlations between the 3-OHAsn amide proton and the Hdna H₂-2 (δ_H 2.36, 2.61) methylene protons. The secondary amide NH signal (δ_H 7.88) of 3-OHGln correlated with the C-1 carbonyl (δ_C 171.8) of 3-OHAsn in the HMBC spectrum, which connected these residues, while the 3-OHGln α -methine (δ_H 4.52) showed a ROESY correlation with the amide NH (δ_H 8.75) of Dab. The amino acid sequence was further extended by a ROESY between the Dab α -methine (δ_H 4.56) and the secondary amide NH (δ_H 9.98) of 3,4-DiMeGln. An HMBC correlation from the Thr NH (δ_H 8.93) to C-1 (δ_C 174.1) of 3,4-DiMeGln linked these two residues, while an HMBC from 3-OMeAla NH (δ_H 8.47) to the Thr carbonyl (δ_C 172.9) joined these subunits. ROESY interactions observed between the α -methine (δ_H 4.48) of 3-OMeAla and the Gly NH (δ_H 9.08), and between the Gly methylene resonances (δ_H 3.51, 3.95) and the Leu NH (δ_H 7.20) helped define neighboring residues. HMBC correlations between the methyl group (δ_H 2.93) of *N*MeGln and the Leu carbonyl (δ_C 174.0), and between the 3-OMeTyr NH (δ_H 8.23) and C-1 (δ_C 170.8) of *N*MeGln linked these residues. An HMBC correlation from the methyl group (δ_H 2.68) of *N*MeAla to the 3-OMeTyr carbonyl (δ_C 170.0) completed the amino acid sequence. An ester bond linking *N*MeAla and the Thr residue was evident from the deshielded chemical shift of the Thr oxymethine (δ_H 5.60) and an HMBC correlation from this proton to the *N*MeAla carbonyl (δ_C 171.4). Thus the planar structure of **1** was elucidated.

The absolute configurations of *L*-*N*MeAla, *L*-*N*MeGln, *L*-Leu, *D*-*allo*-Thr, *D*-3-OMeAla, (2*R*, 3*R*)-3-OHGln, and (2*R*, 3*S*)-3-OHAsn were determined by LC-MS analysis of the acid hydrolysate derivatized with Marfey's reagent and comparison with appropriate amino acid standards. Both the *L*- and *D*-FDLA derivatives were prepared and analyzed for amino acids with multiple chiral centers for which a complete set of standards was not available.⁵ Due to decomposition of β -OMeTyr during acid hydrolysis of **1**, this residue was converted to β -OMeAsp via ozonolysis prior to acid hydrolysis and derivatization, as described by

Zampella et al.⁶ Samples of **1**, callipeltin A,⁷ and papuamide B⁸ were ozonized and hydrolyzed, and then subjected to Marfey's analysis. Both the L- and D-FDLA derivatives were prepared and ion selective monitoring for β -OMeAsp [m/z 458, (M+H)⁺] of the hydrolysates from all three peptides showed the same retention times (Supplementary data) corresponding to (2*R*,3*S*)-3-OMeAsp. Thus the configuration of the β -OMeTyr residue in **1** was assigned as 2*R*,3*R*.⁶ The coupling constant (9.8 Hz) between H-2 (δ_{H} 4.92) and H-3 (δ_{H} 4.53) of this residue was in good agreement with those of callipeltin A and papuamide B, which also have a (2*R*,3*R*)-3-OMeTyr, while neamphamide⁹ contains (2*S*,3*R*)- β -OMeTyr and its oxymethine proton (H-3, d_{H} 5.03) appears as a broadened singlet. These data supported the (2*R*,3*R*)-configuration of β -OMeTyr in **1**. Comparison by LC-MS of both the L- and D-FDLA derivatives of 3,4-DiMeGln and Dab of **1** with similar derivatives from the hydrolysates of authentic samples of callipeltin A and/or papuamide B indicated these residues have the same configuration in all three peptides. Thus, their configurations were assigned as (2*S*,3*S*,4*R*)-DiMeGln and (2*S*,3*S*)-Dab. As (2*S*,3*S*)-Dab is a common fragment of papuamides and callipeltin A, considerable effort has been made toward its synthesis.¹⁰⁻¹³ In these synthetic studies, the diastereomers of Dab showed distinct differences in the coupling constants, with the H-2/H-3 coupling constant in the (2*R*,3*S*)-isomer being ~3 Hz, while in the (2*S*,3*S*)-diastereoisomer it is 6.1–7 Hz, supporting the presence of (2*S*,3*S*)-Dab in **1**. Thus the absolute configurations of all 17 stereogenic carbons in the amino acid portion of stellettapeptin A (**1**) were successfully established. The polyketide moiety was unstable and it decomposed during repeated cleavage attempts, so the configuration of this portion of **1** could not be assigned.

Stellettapeptin B (**2**) analyzed for a molecular formula of C₆₃H₁₀₃N₁₃O₂₀ by HRESIMS coupled with ¹H and ¹³C NMR spectroscopic data (Supplementary data). Its ¹H and ¹³C NMR spectra were also characteristic of a peptide and suggested that **2** was similar in structure to **1**. Detailed analysis of 2D NMR data of **2** led to the identification of 12 residues: NMeAla, β -OMeTyr, NMeThr, Leu, Gly (2), 3-OMeAla, Thr (2), 3,4-DiMeGln, Dab, and Hdna (Fig. 1). The sequence of these residues was deduced from analysis of ROESY and HMBC correlations, as in **1**. The structure of **2** differed from **1** by the presence of NMeThr, Thr, and Gly in place of NMeGln, 3-OHGln, and 3-OHAsn residues, respectively. Similar to compound **1**, macrocyclic ring closure in **2** was established by an HMBC correlation from the Thr1 oxymethine (δ_{H} 5.65) and the carbonyl (δ_{C} 171.7) of the C-terminal NMeAla residue. The absolute configurations of the amino acid residues of **2** were also determined by Marfey's analysis of the acid hydrolysate using a similar strategy employed with **1**. Compound **2** was shown to have the same absolute configuration for each amino acid residue it has in common with **1**. It was also analyzed for L-NMeThr and both a D-*allo*-Thr and a L-Thr residue. Based on the close structural similarity between compounds **1** and **2**, and the fact that all cyclic depsipeptides in this structural class that form a macrocycle via esterification of the C-terminus with the hydroxyl group of a threonine utilize a D-*allo*-Thr residue, the L-Thr was assigned to be adjacent to the N-terminal Gly residue in **2**.

The anti-HIV activity of **1** and **2** was evaluated in an XTT based cell viability assay using the human T-cell line CEM-SS infected with HIV-1_{RF}.¹⁴ After a six day incubation period, compounds **1** and **2** effectively inhibited the cytopathic effect of HIV-1 infection with EC₅₀

values (concentration at which 50% of the target cells are protected from death by the virus) of 23 and 27 nM, respectively (Fig. 3 and Supplementary data). Direct cytotoxicity of **1** and **2** against the host cells was observed with IC₅₀ values (concentration at which 50% of cells are killed by the test sample) of 367 and 373 nM, respectively.

In conclusion, stellettapeptins A (**1**) and B (**2**) are new depsipeptides with structural features characteristic of the family of anti-HIV peptides which includes the callipeltins,^{6,7,15–17} papuamides,⁸ mirabamides,^{1,18} and neamphamide.⁹ Compounds **1** and **2** contain a previously undescribed polyketide subunit, 3-hydroxy-6,8-dimethylnon-4-enoic acid, and the 3-OH^{Gln} and 3-OH^{Asn} residues in **1** are rarely found in peptides. Compounds **1** and **2** potently inhibited the cytopathic effect of HIV-1 infection, providing additional evidence that this class of peptides may hold promise as anti-HIV agents. Isolation of the stellettapeptins from *Stelletta* sp., which is phylogenetically distinct from sponges the callipeltins and papuamides were isolated from, and the fact that **1** and **2** have characteristic structural features of nonribosomal peptides, suggest a possible microbial origin for the stellettapeptins.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We thank professors Apurba Dutta, University of Kansas, and Anders Broberg, Swedish University of Agricultural Sciences, for synthetic samples of (2*S*,3*R*)- and (2*R*,3*S*)-3-OH-aspartic acid, and threo- and erythro-3-OH-glutamic acid, respectively. We thank the late Prof. Luigi Minale for a sample of callipeltin A, Catherine Hixson (SAIC) for the hydrolysis of **1** and **2**, and S. Tarasov and M. Dyba, Biophysics Resource, Structural Biophysics Laboratory for mass spectral analysis. This project was funded in part with federal funds from the Frederick National Laboratory for Cancer Research, National Institutes of Health (contract HHSN261200800001E). This research was supported in part by the Intramural Research Program of NIH, National Laboratory for Cancer Research, Center for Cancer Research. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government. This research was supported in part by the Korea Institute of Ocean Science & Technology (Grant PE98816 to H.J.S.).

References and notes

1. Lu Z, Van Wagoner RM, Harper MK, Baker HL, Hooper JNA, Bewley CA, Ireland CM. *J. Nat. Prod.* 2011; 74:185. [PubMed: 21280591]
2. El-Naggar M, Piggott AM, Capon RJ. *Org. Lett.* 2008; 10:4247. [PubMed: 18781811]
3. Wegerski CJ, France D, Cornell-Kennon S, Crews P. *Bioorg. Med. Chem.* 2004; 12:5631. [PubMed: 15465341]
4. Piel J. *Nat. Prod. Rep.* 2004; 21:519. [PubMed: 15282634]
5. Fujii K, Ikai Y, Oka H, Suzuki M, Harada K-I. *Anal. Chem.* 1997; 69:5146.
6. Zampella A, D'Orsi R, Sepe V, Casapullo A, Monti MC, D'Auria MV. *Org. Lett.* 2005; 7:3585. [PubMed: 16048348]
7. Zampella A, D'Auria MV, Gomez-Paloma L, Casapullo A, Minale L, Debitus C, Henin Y. *J. Am. Chem. Soc.* 1996; 118:6202.
8. Ford PW, Gustafson KR, McKee TC, Shigematsu N, Maurizi LK, Pannel LK, Williams DE, de Silva ED, Lassota P, Allen TM, Soest RV, Andersen RJ, Boyd MR. *J. Am. Chem. Soc.* 1999; 121:5899.

9. Oku N, Gustafson KR, Cartner LK, Wilson JA, Shigematsu N, Hess S, Pannell LK, Boyd MR, McMahon JB. *J. Nat. Prod.* 2004; 67:1407. [PubMed: 15332865]
10. Bunnage ME, Burke AJ, Davies SG, Millican NL, Bicholson RL, Proberts PM, Smith AD. *Org. Biomol. Chem.* 2003; 1:3708. [PubMed: 14649902]
11. Han H, Yoon J, Janda KD. *J. Org. Chem.* 1998; 63:2045.
12. Robinson AJ, Stanislawski P, Dulholland D, He L, Li H-Y. *J. Org. Chem.* 2001; 66:4148. [PubMed: 11397146]
13. Burke AJ, Davies SG, Hedgecock CJR. *Synlett.* 1996:621.
14. Gulakowski RJ, McMahon MB, Staley PG, Moran RA, Boyd MR. *J. Virol. Methods.* 1991; 33:87. [PubMed: 1719015]
15. D'Auria MV, Zampella A, Gomez-Paloma L, Minale L, Debitus C, Roussakis C, Le Bert V. *Tetrahedron.* 1996; 52:9589.
16. Zampella A, Randazzo A, Borbone N, Luciani S, Trevisi L, Debitus C, D'Auria MV. *Tetrahedron Lett.* 2002; 43:6163.
17. Sepe V, D'Orsi R, Borbone N, D'Auria MV, Bifulco G, Monti MC, Catania A, Zampella A. *Tetrahedron.* 2006; 62:833.
18. Plaza A, Gustchina E, Baker HL, Kelly M, Bewley CA. *J. Nat. Prod.* 2007; 70:1753. [PubMed: 17963357]

Figure 1.
Structures and composition of stellettapeptins A (1) and B (2).

Figure 2.
Key HMBC, ROESY, and COSY correlations for **1**.

Figure 3.

Anti-HIV activity of compounds **1** and **2**. Uninfected cell cultures reveal direct cytotoxicity of the test samples. HIV infected cultures show cytoprotective effects of **1** and **2** against viral infection at lower concentrations, and cytotoxic effects at higher concentrations.

Table 1NMR spectral data for **1** (600 MHz, CD₃OH)

Position	δ_C	δ_H (J in Hz)	HMBC
<i>N</i> MeAla			
1	171.4		
2	51.9	5.42 q (7.0)	1, 3, N-Me, ¹ ₃ -OMeTyr
3	13.3	1.28 d (7.0)	1, 2
N-Me	29.5	2.68 s	2, ¹ ₃ -OMeTyr
<i>3-O</i> MeTyr			
1	170.0		
2	53.8	4.92 ^b dd (10.5, 9.8)	1, 3
3	84.4	4.53 ^a d (9.8)	1, 2, 4, 5, 9
3-OMe	56.9	3.10 s	3
4	129.5		
5, 9	131.5	7.17 d (8.3)	3, 6, 7, 8
6, 8	116.2	6.80 d (8.3)	4, 7
7	158.8		
NH		8.23 d (10.5)	2, ¹ _N MeGln
<i>N</i> MeGln			
1	170.8		
2	55.8	4.76 ^a m	1, 4, N-Me, ¹ _{Leu}
3	25.1	1.29 m	5
		1.54 m	2, 4, 5
4	32.1	1.61 m	2, 3, 5
		1.69 m	2, 3, 5
5	177.9		
5-NH ₂		6.80 br s	4, 5
		7.05 br s	5
N-Me	30.4	2.93 s	2, ¹ _{Leu}
<i>Leu</i>			
1	174.0		
2	49.4	4.72 m	3, ¹ _{Gly}
3	40.7	1.23 m	
		1.61 m	5
4	26.2	1.66 m	3
5	21.5	0.90 ^a d (6.5)	3, 4, 6
6	23.6	0.95 d (6.5)	3, 4, 5
NH		7.20 d (9.2)	¹ _{Gly}
<i>Gly</i>			
1	172.3		
2	44.2	3.51 dd (17.0, 5.2)	1, ¹ ₃ -OMeAla

Position	δ_C	δ_H (J in Hz)	HMBC
		3.95 dd (17.0, 6.1)	1, 1 ₃ -OMeAla
NH		9.08 dd (6.1, 5.2)	2, 1 ₃ -OMeAla
3-OMeAla			
1	172.8 ^a		
2	55.4	4.48 q (7.2)	1, 3, 1 _{Thr}
3	71.6	3.74 m	1, 2, 3-OMe
		3.79 m	1, 2, 3-OMe
3-OMe	59.5	3.39 s	3
NH		8.47 d (7.2)	2, 3, 1 _{Thr}
Thr			
1	172.9 ^a		
2	57.4	5.20 dd (10.2, 2.8)	1, 3, 4
3	71.6	5.60 dq (6.6, 2.6)	4, 1 _{NMeAla}
4	14.8	1.18 d (6.3)	2, 3
NH		8.93 d (10.2)	2, 1 _{3,4} -DiMeGln
3,4-DiMeGln			
1	174.1		
2	59.3	4.09 dd (9.3, 2.9)	1, 3, 3-Me, 4
3	36.8	2.47 m	2, 3-Me, 4-Me, 5
3-Me	17.3	1.28 d (6.9)	2, 3, 4
4	44.9	2.72 m	2, 3, 3-Me, 4-Me, 5
4-Me	14.0	1.32 d (7.1)	3, 4, 5
5	182.4		
5-NH ₂		7.14 br s	4, 5
		7.87a br s	5
NH		9.98 br s	1 _{Dab}
Dab			
1	171.6		
2	56.4	4.56 t (6.1)	1, 3, 4, 1 ₃ -OHGln
3	49.5	3.95 m	
3-NH ₂		7.73 2H, br s	
4	16.8	1.43 d (6.8)	2, 3
NH		8.75 d (6.9)	2, 3, 1 ₃ -OHGln
3-OHGln			
1	172.9 ^a		
2	58.7	4.52 ^a dd (8.5, 1.3)	1, 3
3	68.7	4.75 ^a m	
4	40.6	2.37 m	5
		2.45 m	2, 3, 5
5	176.0		

Position	δ_C	δ_H (J in Hz)	HMBC
5-NH ₂		6.88 br s	4, 5
		7.54 br s	5
		NH 7.88 ^a d (8.5)	2, 3, 1 ₃ -OHAsn
3-OHAsn			
1	171.8		
2	59.5	4.73 dd (6.9, 3.9)	1, 3, 4, 1 _{Hdna}
3	72.7	4.61 br d (3.9)	4
4	176.6		
4-NH ₂		7.36 br s	3, 4
		7.80 br s	4
NH		8.25 d (6.9)	1 _{Hdna}
Hdna			
1	175.2		
2	45.4	2.36 m	1, 3, 4
		2.61 m	1, 3, 4
3	66.6	4.90 ^b m	
4	131.0	5.37 dd (10.5, 9.1)	2, 6
5	139.3	5.21 dd (10.5, 5.0)	3, 4, 6, 6-Me, 7
6	31.3	2.63 m	4, 5, 6-Me, 7
6-Me	22.1	0.92 ^a d (6.7)	5, 6, 7
7	48.2	1.13 2H, m	5, 6, 6-Me, 8
8	26.9	1.57 m	6, 7, 8-Me
8-Me	23.7	0.87 ^a d (6.7)	7, 8
9	23.0	0.88 ^a d (6.7)	7, 8

^a Signals overlapped.

^b Buried under CD₃OH signal.